Use of Casirivimab and Imdevimab for the Treatment of COVID-19.
Cureus
; 14(8): e27766, 2022 Aug.
Article
in En
| MEDLINE
| ID: mdl-36106219
The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2.
Full text:
1
Database:
MEDLINE
Language:
En
Journal:
Cureus
Year:
2022
Type:
Article
Affiliation country:
United States